Role and Mechanism of Hyaluronic Acid-modified Milk Exosomes
in Reversing Pemetrexed Resistance in Lung Adenocarcinoma Cells.
10.3779/j.issn.1009-3419.2025.102.35
- Author:
Lan WU
1
;
Jie LEI
2
;
Hui LI
1
Author Information
1. Affiliated Inner Mongolia Clinical College of Inner Mongolia Medical University, Hohehot 010017, China.
2. Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014040, China.
- Publication Type:Journal Article
- Keywords:
Drug resistance;
Exosomes;
Hyaluronic acid;
Lung neoplasms;
Pemetrexed
- MeSH:
Humans;
Hyaluronic Acid/chemistry*;
Drug Resistance, Neoplasm/drug effects*;
Exosomes/chemistry*;
Adenocarcinoma of Lung/genetics*;
Pemetrexed/pharmacology*;
Animals;
Lung Neoplasms/pathology*;
Milk/chemistry*;
Cell Proliferation/drug effects*;
Apoptosis/drug effects*;
Cell Line, Tumor;
Hyaluronan Receptors/metabolism*
- From:
Chinese Journal of Lung Cancer
2025;28(9):658-666
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Lung cancer currently ranks first globally in both incidence and mortality. Pemetrexed (PMX) serves as a first-line treatment for lung adenocarcinoma (LUAD), but the patients often develop drug resistance during therapy. Milk exosome (mEXO) have the advantages of low immunogenicity, high tissue affinity, and low cost, and mEXO itself has anti-tumor effects. Hyaluronan (HA) naturally bind to CD44, a receptor which is highly expressed in LUAD tissues. This study aims to construct hyaluronan-modified milk exosome (HA-mEXO) and preliminarily investigate their molecular mechanisms for reversing PMX resistance through cellular experiments.
METHODS:Exosomes were extracted from milk using high-speed centrifugation, and HA-mEXO was constructed. PMX-resistant A549 and PC-9 cell lines were treated with mEXO and HA-mEXO, respectively. CCK-8 assays, colony formation assays, Transwell assays, and flow cytometry were performed to evaluate proliferation, colony formation, migration, invasion, and apoptosis phenotypes in the treated resistant cell lines. Finally, transcriptomic sequencing, analysis, and cellular functional recovery experiments were conducted to investigate the mechanism by which HA-mEXO reverses PMX resistance in LUAD cells.
RESULTS:The expression of CD44 in A549 and PC-9 LUAD drug-resistant cell lines was significantly higher than that in parental cells, and the uptake rate of HA-mEXO by drug-resistant cell lines was significantly higher than that of mEXO. Compared to the mEXO group, HA-mEXO-treated A549 and PC-9 resistant cells exhibited significantly reduced half maximal inhibitory concentration (IC50) values for PMX, markedly diminished clonogenic, migratory, and invasive capabilities, and a significantly increased proportion of apoptotic cells. Western blot analysis revealed that, compared to parental cells, A549 and PC-9 drug-resistant cells exhibited downregulated ZNF516 expression and upregulated ABCC5 expression. Immunofluorescence analysis revealed that HA-mEXO treatment downregulated ABCC5 expression in A549 and PC-9 drug-resistant cells compared to the PBS group, whereas co-treatment with HA-mEXO and ZNF516 knockdown showed no significant change in ABCC5 expression.
CONCLUSIONS:HA-mEXO carrying ZNF516 suppress ABCC5 expression, thereby enhancing the sensitivity of A549 and PC-9 LAUD drug-resistant cells to PMX.
